Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids

Clinical and Experimental Allergy

Volumn 31, Issue 3, 2001, Pages 400-408

  Grootendorst, D C ^a,b   Dahlen S E ^c   Van Den Bos, J W ^a   Duiverman, E J ^d   Veselic Charvat, M ^b   Vrijlandt, E J L E ^e   O'Sullivan, S ^c   Kumlin, M ^c   Sterk, P J ^b   Roldaan, A C ^a,f  

^a Dutch Asthma Centre   (Switzerland)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

^d JULIANA CHILDREN S HOSPITAL   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

^f LEYENBURG HOSPITAL   (Netherlands)

Author keywords

9 11 PGF2; Allergen avoidance; EPX; High altitude; House dust mite; Induced sputum; LTE4; Severe asthma; Urine

Indexed keywords

ADENOSINE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; EOSINOPHIL PROTEIN X; FLUTICASONE PROPIONATE; HISTAMINE; HOUSE DUST ALLERGEN; LEUKOTRIENE E4; LONG ACTING DRUG; NEDOCROMIL; PREDNISOLONE; PROSTAGLANDIN F2; THEOPHYLLINE;

ADOLESCENT; ALLERGIC ASTHMA; ALTITUDE; ARTICLE; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE MARKER; DISEASE SEVERITY; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; FEMALE; HOME; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; QUALITY OF LIFE; SEA LEVEL; SPUTUM ANALYSIS; SPUTUM LEVEL; TREATMENT OUTCOME; URINALYSIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ALLERGENS; ANIMALS; ASTHMA; DUST; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MALE; MITES; STEROIDS;

EID: 0035725594     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01022.x     Document Type: Article

References (32)

1. The cellular and mediator basis of asthma in relation to natural history
2. Sensitization to house dust mites as a dominant risk factor for asthma among adolescents living in central Virginia: Multiple regression analysis of a population-based study
3. Exposure to house dust mite allergens and the clinical activity of asthma
4. Allergen avoidance in the treatment of asthma and atopic disorders
5. House dust mite control measures in the management of asthma: Meta-analysis
6. Altitude and house dust mites
7. Pulmonary function and bronchial hyperreactivity in asthmatic children with house dust mite allergy during prolonged stay in the Italian alps (Misurina, 1756m)
8. Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposure
9. Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma
10. Effective allergen avoidance at high altitude reduces allergen-induced bronchial hyperresponsiveness
11. Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma
12. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids
13. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids
14. Urinary eosinophil protein X in relation to disease activity in childhood asthma
15. 4 in humans
16. 2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction
17. Asthma control versus asthma severity
18. The British guidelines on asthma management. 1995 review and position statement
19. Measuring quality of life in children with asthma
20. Should study subjects see their previous responses: Data from a randomized controlled trial
21. Lung volumes and forced ventilatory flows
22. Spirometric reference values for white European children and adolescents: Polgar revisited
23. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults
24. Induced sputum in adolescents with severe, stable asthma. Safety and relationship of cell counts and ECP to clinical severity
25. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma
26. Transcription factors and asthma
27. 4 excretion
28. Inhaled glucocorticoids: New developments relevant to updating of the asthma management guidelines
29. One year treatment with salmeterol compared with beclomethasone in children with asthma
30. Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma
31. Clinical control and histopathological outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment